Segment Information (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Summary of Financial Information for the Company's Segments

Summarized financial information for the Company’s segments is shown in the following tables:

(in thousands)	Year Ended December 31,
	2023		2022
Revenue
Patient services	$	213,504	$	166,785
Dispensary	103,835		79,343
Clinical trials & other	6,900		6,355
Consolidated revenue	324,239		252,483
Direct costs
Patient services	181,017		134,761
Dispensary	83,071		65,111

(in thousands)	Year Ended December 31,
	2023		2022
Clinical trials & other	578		518
Total segment direct costs	264,666		200,390
Depreciation expense
Patient services	2,156		1,202
Dispensary	106		4
Clinical trials & other	1		1
Total segment depreciation expense	2,263		1,207
Amortization of intangible assets
Patient services	2,799		2,675
Clinical trials & other	210		211
Total segment amortization	3,009		2,886
Operating income
Patient services	27,532		28,147
Dispensary	20,658		14,228
Clinical trials & other	6,111		5,625
Total segment operating income	54,301		48,000
Goodwill impairment charges
Patient services	16,235		9,944
Clinical trials & other	632		—
Total impairment charges	16,867		9,944
Selling, general and administrative expense	113,851		119,689
Non-segment depreciation and amortization	601		318
Total consolidated operating loss	$	(77,018)	$	(81,951)

(in thousands)	December 31, 2023		December 31, 2022
Assets
Patient services	$	73,551	$	64,869
Dispensary	8,378		7,194
Clinical trials & other	8,878		11,496
Non-segment assets	118,433		178,106
Total assets	$	209,240	$	261,665